Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found.

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine ...

Osaka Metropolitan University-led researchers verified the therapeutic effects of plasma-activated medium on synovial sarcoma ...

Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan ...

An artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone, ...

Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different ...

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2 ...